Alzheimer's Disease Long-term Follow-up Study (ALF Study)
Phase 4
Completed
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00165724
- Lead Sponsor
- Eisai Korea Inc.
- Brief Summary
Open study for efficacy and safety of donepezil treatment during 48 weeks
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method ADAS-cog
- Secondary Outcome Measures
Name Time Method MMSE, CDR, GDS, NPI, ADL, SSDQ
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie donepezil's efficacy in Alzheimer's disease progression as studied in NCT00165724?
How does donepezil compare to other acetylcholinesterase inhibitors in managing Alzheimer's symptoms during long-term treatment?
What biomarkers correlate with response to donepezil in Alzheimer's patients from the ALF Study (NCT00165724)?
What adverse events were reported in Eisai Korea's 48-week donepezil trial for Alzheimer's (NCT00165724)?
How do cholinesterase inhibitors like donepezil interact with amyloid-beta pathology in Alzheimer's disease phase 4 trials?
Trial Locations
- Locations (7)
Bobath Memorial Hospital
🇰🇷Bundang, Korea, Republic of
Bundang Seoul National University Hospital
🇰🇷Bundang, Korea, Republic of
Changwon Fatima Hospital
🇰🇷Changwon, Korea, Republic of
Yeungnam University Hospital
🇰🇷Daegu, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Catholic University Hospital
🇰🇷Seoul, Korea, Republic of
Eulji University Hospital
🇰🇷Seoul, Korea, Republic of
Bobath Memorial Hospital🇰🇷Bundang, Korea, Republic of